Breaking News Egalet's abuse-deterrent oxycodone safe in long-term study; shares up 81% Results from a Phase 3 study assessing the safety of Egalet's (EGLT +80.7%) abuse-deterrent oxycodone, Egalet-002, showed the opioid to be safe and well-tolerated with the incidence of adverse events consistent with an extended-release oxycodone.The open-label 281-subject study evaluated the safety and tolerability of Egalet-002 for up to 56 weeks in opioid-experienced patients with moderate-to-severe chronic noncancer pain. About 150 participants received Egalet-002 for six months while ~50 received it for one year.Another Phase 3 assessing the safety and efficacy of Egalet-002 in chronic pain patients will wind up next month.Egalet-002 incorporates the company's Guardian Technology which uses injection molding to create a hard matrix designed to make the pill difficult to crush, grind, chew or dissolve. It also turns to gel when exposed to water. Today, 3:26 PM |11 Comments https://seekingalpha.com/news/search?query=eglt
Always consult an Investment Professional, all communications about stocks from me are my own opinions, and not for investing decisions
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.